{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:42:50Z","timestamp":1779169370602,"version":"3.51.4"},"reference-count":50,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2311507","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:13:34Z","timestamp":1706674414000},"page":"279-291","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of pembrolizumab for previously treated MSI-H\/dMMR solid tumours in the UK"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-8598","authenticated-orcid":false,"given":"Grant","family":"McCarthy","sequence":"first","affiliation":[{"name":"MSD (UK) Ltd","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-9871","authenticated-orcid":false,"given":"Kate","family":"Young","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Madin-Warburton","sequence":"additional","affiliation":[{"name":"Lumanity","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Mantaian","sequence":"additional","affiliation":[{"name":"Lumanity","place":["Las Vegas, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Brook","sequence":"additional","affiliation":[{"name":"Lumanity","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaylie","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"Lumanity","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5233-4756","authenticated-orcid":false,"given":"Jan","family":"Mikelson","sequence":"additional","affiliation":[{"name":"MSD","place":["Zurich, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Seyla-Hammer","sequence":"additional","affiliation":[{"name":"MSD (UK) Ltd","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-6966","authenticated-orcid":false,"given":"Raquel","family":"Aguiar-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Merck Canada Inc","place":["Kirkland, Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Amonkar","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02105"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8484122"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01620-7"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1807929"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0332"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1091-8"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.009"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0043"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0012"},{"key":"e_1_3_6_15_1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017 [2023 Jul 21]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02107"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_6_18_1","unstructured":"National Institute for Health and Care Excellence (NICE). Entrectinib for treating NTRK fusion-positive solid tumours. Technology appraisal guidance [TA644]; 2020 [2023 Jun 26]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta644"},{"key":"e_1_3_6_19_1","unstructured":"National Institute for Health and Care Excellence (NICE). Larotrectinib for treating NTRK fusion-positive advanced solid tumours. Technology appraisal guidance [TA630]; 2020 [2023 Jun 26]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta630"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.04.218"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1354"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta25760"},{"key":"e_1_3_6_23_1","unstructured":"National Institute for Health and Care Excellence (NICE). The NICE methods of health technology evaluation: the case for change. 2020 [2023 Jun 28]. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/our-programmes\/nice-guidance\/chte-methods-consultation\/NICE-methods-of-health-technology-evaluation-case-for-change.docx"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2043634"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1917140"},{"key":"e_1_3_6_26_1","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. 2022 [2023 Jun 26]. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case"},{"key":"e_1_3_6_27_1","unstructured":"Cancer Research UK. Bowel cancer incidence by sex and UK region. 2018 [2022 Nov 22]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bowel-cancer\/incidence#heading-Zero"},{"key":"e_1_3_6_28_1","unstructured":"Cancer Research UK. Uterine cancer incidence by sex and UK region. 2018 [2022 Nov 22]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/uterine-cancer\/incidence#heading-Three"},{"key":"e_1_3_6_29_1","unstructured":"Cancer Research UK. Stomach cancer incidence. 2018 [2022 Nov 22]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/stomach-cancer#heading-Zero"},{"key":"e_1_3_6_30_1","unstructured":"Cancer Research UK. Small intestine cancer incidence. 2018 [2022 Nov 22]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/small-intestine-cancer#heading-Zero"},{"key":"e_1_3_6_31_1","unstructured":"National Institute for Health and Care Excellence (NICE). Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. 2021 [2022 Jan 19]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta722"},{"key":"e_1_3_6_32_1","unstructured":"MSD. Microsatellite instability-high advisory board meeting. Data on file. 2022."},{"key":"e_1_3_6_33_1","unstructured":"MSD BV. Keytruda (pembrolizumab). Summary of product characteristics. 2020 [2023 Jun 26]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6111"},{"key":"e_1_3_6_36_1","unstructured":"Hern\u00e1ndez Alava M Pudney S Wailoo A. Estimating EQ-5D by age and sex for the UK. NICE DSU Report; 2022 [2023 Jul 20]. Available from: https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/DSU%20Age%20based%20utility%20-%20Final%20for%20website.pdf"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"e_1_3_6_38_1","unstructured":"Monthly Index of Medical Specialities (MIMS). MIMS. [cited 2022 Oct 20]. Available from. https:\/\/www.mims.co.uk\/"},{"key":"e_1_3_6_39_1","unstructured":"Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT). 2021. Available from: https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit"},{"key":"e_1_3_6_40_1","unstructured":"National Health Service. 2020\/21 National Cost Collection Data Publication. 2022 [2023 Jun 28]. Available from: https:\/\/www.england.nhs.uk\/publication\/2020-21-national-cost-collection-data-publication\/"},{"key":"e_1_3_6_41_1","unstructured":"Unit Costs of Health and Social Care 2019 PSSRU. 2019. Available from: https:\/\/www.pssru.ac.uk\/pub\/uc\/uc2019\/sources-of-information.pdf"},{"key":"e_1_3_6_42_1","unstructured":"National Institute for Health and Care Excellence (NICE). Diagnostics guidance [DG27]: molecular testing strategies for Lynch syndrome in people with colorectal cancer. 2017 [2023 Mar 22]. Available from: https:\/\/www.nice.org.uk\/guidance\/dg27\/informationforpublic"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11313"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216315595203"},{"key":"e_1_3_6_46_1","unstructured":"National Institute for Health and Care Excellence (NICE). TA488: regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours. 2017 [2021 Jan 12]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta488\/"},{"key":"e_1_3_6_47_1","unstructured":"Schneider P McNamara S Love-Koh J Doran T Gutacker N. QALY Shortfall Calculator. 2021 [2023 Jun 26]. Available from: https:\/\/shiny.york.ac.uk\/shortfall\/"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.343"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-022-00740-1"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/0470092602.ch3"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1399"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2311507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:42:20Z","timestamp":1772779340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2311507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2311507"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2311507","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}